Mirae Asset Global Investments Co., Ltd. Axsome Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,615 shares of AXSM stock, worth $175,792. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,615

Previous 1,736 6.97%

Holding current value

$175,792

Previous $155,000 12.26%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$83.08 - $100.49 $10,052 - $12,159	-121 Reduced 6.97%	1,615 $136,000
Q3 2024 Oct 23, 2024	BUY	$78.93 - $95.84 $25,099 - $30,477	318 Added 22.43%	1,736 $155,000
Q2 2024 Jul 30, 2024	SELL	$65.72 - $80.5 $908,973 - $1.11 Million	-13,831 Reduced 90.7%	1,418 $114,000
Q1 2024 May 01, 2024	SELL	$69.39 - $97.64 $188,255 - $264,897	-2,713 Reduced 15.1%	15,249 $1.22 Million
Q4 2023 Jan 24, 2024	BUY	$57.42 - $83.61 $4,134 - $6,019	72 Added 0.4%	17,962 $1.43 Million
Q3 2023 Oct 26, 2023	BUY	$69.25 - $82.21 $183,166 - $217,445	2,645 Added 17.35%	17,890 $1.25 Million
Q2 2023 Aug 10, 2023	BUY	$58.41 - $90.35 $19,216 - $29,725	329 Added 2.21%	15,245 $1.1 Million
Q1 2023 May 04, 2023	SELL	$58.39 - $75.0 $1,518 - $1,950	-26 Reduced 0.17%	14,916 $920,000
Q4 2022 Feb 09, 2023	BUY	$39.94 - $79.72 $71,652 - $143,017	1,794 Added 13.64%	14,942 $1.15 Million
Q3 2022 Nov 10, 2022	BUY	$36.06 - $69.85 $474,116 - $918,387	13,148 New	13,148 $587,000

Others Institutions Holding AXSM

# of Institutions

329

Shares Held

37.8M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $4.67B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Axsome Therapeutics, Inc. Transaction History